ClinicalTrials.gg
RecruitingNCT06872333Updated Jun 4, 2026

Allo HSCT for High Risk Hemoglobinopathies

A Phase 2 interventional study of Alemtuzumab and Total Body Irradiation in Graft Failure, Sickle Cell Disease and Hemoglobinopathies, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged Up to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2024, registered Mar 2025).
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
Up to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing sirolimus in Anemia, Sickle Cell — 5 open to participants now, 11 under way, none of them phase 3. Sirolimus · Anemia, Sickle Cell.

Planned enrollment
4th of 15
62 · median 46
Started
2024
the only one that year
Phase 2
9 of 15
5 open now
Primary completion
2030-06
later than 8 of 10 live
Registered
14th of 15
by date
Lead sponsor
1 of 15
Masonic Cancer Center, University of Minnesota

Among the 15 studies testing sirolimus in Anemia, Sickle Cell, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is one of 9 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 14th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

5 of the 15 studies testing sirolimus in Anemia, Sickle Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: Up to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing sirolimus in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

03

Conditions studied

  • Graft Failure
  • Sickle Cell Disease
  • Hemoglobinopathies
04

Who can participate

Ages eligible
Up to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sickle Cell Disease (SCD)
  • SCD Patients with a fully matched sibling donor (MSD) irrespective of the frequency or severity of symptoms MSD transplant can be considered. Parents/patient must be counseled as to the risks and benefits and provide their voluntary
  • Transfusion Dependent Alpha- or Beta- Thalassemia
  • Diamond Blackfan Anemia
  • Other Non-Malignant Hematologic Disorders
  • ≥ 60%, Lansky play score ≥ 60. Patients with lower performance score can be considered based on study team's evaluation.
  • Sexually active persons of or persons with partners of childbearing potential must agree to use a highly effective form of during study treatment and for at least 4 months after the transplant.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding or intending to become pregnant during the study. Persons of must have a negative pregnancy test (serum or urine) within 30 days of the start of treatment
  • infection with a detectable viral load. All HIV+ patients must be evaluated by infectious disease (ID) and an HIV management plan established prior to transplantation.
  • Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
  • Known allergy to any of the study components
  • Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
  • Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Arm A - Closed

    Arm A Matched sib regimen - Age 6 -55 (per physician preference for patients over 6) Campath/TBI

    Drug: Alemtuzumab · Radiation: Total Body Irradiation · Biological: Cell Infusion · Drug: Sirolimus · Drug: Mycophenolate Mofetil

  • Experimental
    Arm B

    Arm B Matched sib regimen - 0-55 (per physician preference for patients over 6) ATG/Flu/Bu

    Biological: Cell Infusion · Drug: Thymoglobulin · Drug: Fludarabine · Drug: Busulfan · Drug: Tacrolimus · Drug: Mycophenolate Mofetil

  • Experimental
    Arm C

    Arm C Fully Matched unrelated donor (MUD)- - 0-55 years; ATG/Flu/Bu

    Biological: Cell Infusion · Drug: Thymoglobulin · Drug: Fludarabine · Drug: Busulfan · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Drug: Plerixafor (mozobil)

  • Experimental
    Arm D

    Arm D: Haploindentical or mismatched unrelated donors (MMUD) - 0-55 years; ATG/Thiotepa/Cyclophosphamide/MESNA/Flu/TBI

    Drug: Sirolimus · Drug: Tacrolimus · Drug: Plerixafor (mozobil)

  • Experimental
    Arm E

    Matched sib regimen - Age 6-55 (per physician preference for patients over 6) Campath/TBI with peripheral blood stem cell graft

    Radiation: Total Body Irradiation · Biological: Cell Infusion · Drug: Thymoglobulin · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Sirolimus · Drug: Tacrolimus · Drug: Mycophenolate Mofetil

Interventions

  • Alemtuzumab (Campath) will be administered IV over 2 hours on day -8 to day -4.

    Also known as: Campath

  • RadiationTotal Body Irradiation

    400 cGy in 2 split fractions will be administered per Department of RadiationOncology SOPs.

    Also known as: TBI

  • BiologicalCell TypesStudies of Cell TypesCell Types pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    On day 0 the cells will be infused per cell source specific institutional guidelines

  • ATG will be administered IV every 24 hours beginning on day -8 for all patients. Dosing will be model-based using Bayesian methodology13,14,15. Total doses and total number of doses (1-4 doses) will be determined based on absolute lymphocyte count and weight.

    Also known as: Rabbit ATG

  • Fludarabine will be administered IV over 1 hour every 24 hours on day -5 to day - 2. The daily dose of fludarabine will be determined by model-based dosing utilizing Bayesian methodology with a cumulative area under the curve (cAUC) of 20 mg\*hr/L (range 18-22 mg\*hr/L).

  • Busulfan dosing and administration and therapeutic drug monitoring (TDM) per institutional guidelines. Initial busulfan dosing will be determined by model-based dosing utilizing Bayesian methods with a cumulative area under the curve (cAUC) of 75 mg\*hr/L.

  • Cyclophosphamide will be administered at a dose of 14.5 mg/kg over 2 hours IV daily on days -6 and -5. Cyclophosphamide dosing is calculated based on actual body weight (ABW). For Arm D - Cyclophosphamide 50 mg/kg IV will be administered over 2 hours on days +3 and +4. Cyclophosphamide dosing for post-transplant is calculated based on ideal body weight (IBW) unless patient weighs less than IBW, in which case actual body weight (ABW) will be used.

    Also known as: Cyclophosphamide with MESNA

  • Patients on Arm A and Arm D will receive sirolimus; beginning on day -3 and continuing until day +180 for patients on Arm A or beginning on day +5 and continuing until 1 year post transplant for patients on Arm D.

  • Patients on Arm B and Arm C will receive tacrolimus, beginning on day -3 and continuing until day +180. Tacrolimus dosing and monitoring will be per institutional guidelines.

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MMF will begin on day -3 (Arm A, B \& C) or day +5 (Arm D). Patients treated on adult service will receive 15 mg/kg (max 1500 mg/dose) given every 12 hours, rounded to nearest 250 mg. Patients on pediatric service will receive 15 mg/kg (max 1000 mg/dose) given every 8 hours. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. MMF will be stopped at day +30 (Arms A, B \& C) or day +35 (Arm D) or 7 days after engraftment, whichever day is later, if no acute GVHD.

    Also known as: (MMF)

  • DrugPlerixaforStudies of PlerixaforPlerixafor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Plerixafor will beused to significantly increase stem cell yields on a second collection day compared to donors who continued mobilization on G-CSF only.

06

What researchers measure

Primary outcomes

  1. Incidence of Graft versus Host Disease (GvHD)

    Time frame: 1 year

Secondary outcomes

  1. Overall Survival

    Overall survival post HCT

    Time frame: 1 and 2 years

  2. Grade 3-4 Acute GvHD

    Grade 3-4 acute Graft versus Host Disease (GvHD) at 2 years post HCT.

    Time frame: 2 years

  3. Chronic Graft versus Host Disease (GvHD) Free

    Chronic Graft versus Host Disease (GvHD) Free at 2 years post HCT.

    Time frame: 2 years

  4. Failure Free Survival

    Failure Free Survival 2 years post HCT.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2030, 66 months after the start.

Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 66 months is above that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 12, 2025
StartActual
Nov 19, 2024
Primary completionEst.
Jun 1, 2030
CompletionEst.
Jun 1, 2032
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06872333
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Nov 19, 2024
Primary completion
Jun 1, 2030 (estimated)
Completion
Jun 1, 2032 (estimated)
Last update
Jun 4, 2026

Study contacts

Ashish Gupta, MBBS, MPH
Contact
gupta461@umn.edu
612-626-2961

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cell Types · Sirolimus · Tacrolimus · Plerixafor

Start the discussion